Skip to Content

Join the 'Acute Lymphoblastic Leukemia' group to help and get support from people like you.

Acute Lymphoblastic Leukemia News

FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

Posted 9 Apr 2018 by Drugs.com

March 29, 2018 – The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen under the microscope. In patients who have achieved ...

Cancer Survival Rates Vary Across the World

Posted 31 Jan 2018 by Drugs.com

WEDNESDAY, Jan. 31, 2018 – Cancer survival rates are improving worldwide, but poorer countries are seeing less improvement than wealthier ones, a new study shows. Researchers analyzed data from 2000 to 2014 to assess five-year cancer survival rates among 37.5 million children and adults diagnosed with one of 18 common cancers. These patients were from 71 countries and territories. After taking ...

FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

Posted 31 Aug 2017 by Drugs.com

South San Francisco, CA – August 30, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and ...

First Gene Therapy Kymriah (tisagenlecleucel) Approved in U.S.

Posted 30 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 30, 2017 – The U.S. Food and Drug Administration on Wednesday approved the first gene therapy in the United States, to treat children and young adults with a particularly tough type of leukemia. Kymriah (tisagenlecleucel) is for B-cell acute lymphoblastic leukemia (ALL), the agency said in a news release. "We're entering a new frontier in medical innovation with the ability to ...

FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia

Posted 30 Aug 2017 by Drugs.com

August 30, 2017 – The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). ...

FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia

Posted 21 Aug 2017 by Drugs.com

August 17, 2017 – The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). “For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low,” said Richard Pazdur, M.D., dir ...

Besponsa (Inotuzumab Ozogamicin) Approved for Deadly Blood Cancer

Posted 18 Aug 2017 by Drugs.com

THURSDAY, Aug. 17, 2017 – The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL). B-cell ALL is a rapidly growing cancer that occurs when the bone marrow makes too many B-cell lymphocytes, a type of white blood cell. Almost 6,000 people in the United States are likely to be diagnosed with ...

FDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.

Posted 13 Jul 2017 by Drugs.com

WEDNESDAY, July 12, 2017 – A U.S. Food and Drug Administration advisory panel on Wednesday gave unanimous approval to what could soon be the first gene therapy to be marketed in the United States. The treatment, called CTL019, genetically tweaks a patient's own immune system cells into what scientists call "a living drug" to battle a form of acute lymphoblastic leukemia (ALL), The New York Times ...

FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

Posted 12 Jul 2017 by Drugs.com

THOUSAND OAKS, Calif., July 11, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. The approval converts Blincyto's accelerated approval to a full approval. The sBLA approval also ...

Childhood Cancer Survivors Now Living Healthier Lives

Posted 2 Jun 2017 by Drugs.com

FRIDAY, June 2, 2017 – For people who battled cancer in childhood, the prospects for a long life without cancer recurrence or chronic illness are better than ever, a new study finds. That's largely due to changes in cancer treatment protocols that have meant less toxicity to children and less chance for long-term side effects, researchers said. This is the first "comprehensive" study on the ...

FDA Approves Xatmep (methotrexate) Oral Solution

Posted 27 Apr 2017 by Drugs.com

Denver, April 26, 2017 — Silvergate Pharmaceuticals, Inc. leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Xatmep (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution. Xatmep is indicated for the treatment of acute lymphoblastic l ...

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study

Posted 9 Mar 2017 by Drugs.com

WEDNESDAY, March 8, 2017 – The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment – with no signs of additional safety risks, a new study finds. Gleevec – known generically as imatinib – was hailed as a "wonder drug" when it was introduced in 2001 for treating chronic myeloid leukemia (CML). CML is a type of blood cancer that strikes about 5,000 ...

Gene Therapy Helps 2 Babies Fight Type of Leukemia

Posted 25 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 25, 2017 – Two infants with an advanced form of leukemia are in remission after treatment with genetically tweaked immune system cells, British researchers report. Both babies had run out of treatment options for their cancer, known as B-cell acute lymphoblastic leukemia, or ALL. But, after treatment with genetically altered T-cells – a type of immune system cell – both went ...

Experimental Immune Cell Rx Shows Promise for Leukemia

Posted 21 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 21, 2016 – An experimental therapy that revs up the immune system's cancer-fighting ability may help treat some leukemia patients who face a grim prognosis, a small study suggests. The treatment involves infusions of "natural killer" (NK) cells taken from a healthy donor and chemically "trained" to go after tumor cells. Researchers found that of nine patients with acute myeloid ...

FDA Approves Blincyto (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Posted 5 Sep 2016 by Drugs.com

THOUSAND OAKS, Calif., Sept. 1, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute ...

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Leukemia

Related Drug Support Groups

methotrexate, Gleevec, Sprycel, mercaptopurine, imatinib, doxorubicin, dasatinib, Adriamycin, Kymriah, view more... Oncaspar, Iclusig, Purinethol, Besponsa, Methotrexate LPF Sodium, tisagenlecleucel, Adriamycin RDF, Marqibo, Adriamycin PFS, Erwinaze, Purixan, Blincyto, Xatmep, Folex PFS, clofarabine, Arranon, Clolar, Vumon, inotuzumab ozogamicin, blinatumomab, ponatinib, vincristine liposomal, asparaginase erwinia chrysanthemi, teniposide, pegaspargase, nelarabine, Trexall